Provided by Tiger Fintech (Singapore) Pte. Ltd.

Intellia Therapeutics

8.31
+0.39004.92%
Post-market: 8.530.2290+2.76%19:58 EDT
Volume:2.83M
Turnover:23.11M
Market Cap:860.23M
PE:-1.58
High:8.33
Open:7.94
Low:7.86
Close:7.92
Loading ...

Intellia Therapeutics Q4 Net Loss Narrows; Shares Rise Pre-Bell

MT Newswires Live
·
27 Feb

Intellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
27 Feb

Intellia Therapeutics Q4 Net Income USD -128.898 Million

Reuters
·
27 Feb

Earnings Flash (NTLA) Intellia Therapeutics Posts Q4 Collaboration Revenue $12.9M, vs. FactSet Est of $8.6M

MT Newswires Live
·
27 Feb

Earnings Flash (NTLA) Intellia Therapeutics Posts Q4 Net Loss $-1.27 a Share, vs. FactSet Est of $-1.33 Loss

MT Newswires Live
·
27 Feb

Intellia Therapeutics Q4 2024 GAAP EPS $(1.27) Beats $(1.36) Estimate, Sales $12.87M Beat $8.53M Estimate

Benzinga
·
27 Feb

Intellia Therapeutics Q4 Basic EPS USD -1.27

THOMSON REUTERS
·
27 Feb

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Company Progress

GlobeNewswire
·
27 Feb

Praxis Precision Medicines, Inc. (PRAX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Zacks
·
25 Feb

Intellia Therapeutics Inc expected to post a loss of $1.33 a share - Earnings Preview

Reuters
·
25 Feb

What's in Store for These 5 Biotech Stocks This Earnings Season?

Zacks
·
24 Feb

CRSP Stock Rises 25% in a Week: Time to Buy, Hold or Sell?

Zacks
·
18 Feb

Will Intellia Therapeutics (NASDAQ:NTLA) Spend Its Cash Wisely?

Simply Wall St.
·
15 Feb

NTLA LAWSUIT ALERT: Levi & Korsinsky LLP Notifies Intellia Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

TIPRANKS
·
12 Feb

Intellia Therapeutics Inc. (NTLA): Among Cathie Wood’s Top Stock Picks for 2025

Insider Monkey
·
07 Feb

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
05 Feb

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
05 Feb

Intellia Therapeutics Shares Fall After Morgan Stanley Downgrade

MT Newswires Live
·
28 Jan

Update: Morgan Stanley Downgrades Intellia Therapeutics to Equal Weight From Overweight, Cuts Price Target to $11 From $56

MT Newswires Live
·
28 Jan

Morgan Stanley Downgrades Intellia Therapeutics to Equal Weight From Overweight, $56 Price Target

MT Newswires Live
·
27 Jan